Dashboard
Manage Tickers

RGNX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regenxbio-q1-2024-gaap-eps-138-misses-123-estimate-sales-15622m-miss-23525m-estimate
Regenxbio Q1 2024 GAAP EPS $(1.38) Misses ...
05/08/2024 21:37:56

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.23) b...

where-regenxbio-stands-with-analysts
Where Regenxbio Stands With Analysts
04/12/2024 16:01:22

stifel-maintains-buy-on-regenxbio-maintains-40-price-target
Stifel Maintains Buy on Regenxbio, Maintai...
04/12/2024 15:53:51

Stifel analyst Annabel Samimy maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $40 price target.

Core News & Articles
REGENXBIO Announces Lancet Publication of ...
03/28/2024 11:09:41

REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and to...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
03/25/2024 21:32:19

hc-wainwright--co-initiates-coverage-on-regenxbio-with-buy-rating-announces-price-target-of-36
HC Wainwright & Co. Initiates Coverage On ...
03/11/2024 13:39:24

HC Wainwright & Co. analyst Yi Chen initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price ...

this-gene-therapy-player-duchenne-data-is-impressive-analyst-upgrades-regenxbio
This Gene Therapy Player Duchenne Data Is ...
03/08/2024 18:43:05

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 t...

regenxbio-shares-are-trading-higher-after-rbc-capital-upgraded-the-stock-from-sector-perform-to-outperform-and-raised-its-price-target-from-20-to-35
Regenxbio shares are trading higher after ...
03/08/2024 13:48:00

rbc-capital-upgrades-regenxbio-to-outperform-raises-price-target-to-35
RBC Capital Upgrades Regenxbio to Outperfo...
03/08/2024 12:59:17

RBC Capital analyst Luca Issi upgrades Regenxbio (NASDAQ:RGNX) from Sector Perform to Outperform and raises the price target...

chardan-capital-maintains-buy-on-regenxbio-maintains-52-price-target
Chardan Capital Maintains Buy on Regenxbio...
03/07/2024 14:45:05

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.

barclays-maintains-overweight-on-regenxbio-raises-price-target-to-55
Barclays Maintains Overweight on Regenxbio...
03/07/2024 12:16:56

Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $45 to $55.

regenxbio-prices-upsized-public-offering-of-4565260-common-shares-at-23share-and-1521740-pre-funded-warrants-at-229999warrant
REGENXBIO Prices Upsized Public Offering O...
03/07/2024 07:44:07

 The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offer...

regenxbio-announces-proposed-125m-public-offering-of-common-stock
REGENXBIO Announces Proposed $125M Public ...
03/06/2024 21:30:42

REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of i...

leerink-partners-upgrades-regenxbio-to-outperform
Leerink Partners Upgrades Regenxbio to Out...
03/06/2024 14:33:01

Leerink Partners analyst Mani Foroohar upgrades Regenxbio (NASDAQ:RGNX) from Market Perform to Outperform.

beyond-the-numbers-4-analysts-discuss-regenxbio-stock
Beyond The Numbers: 4 Analysts Discuss Reg...
03/06/2024 13:00:56

baird-maintains-outperform-on-regenxbio-raises-price-target-to-39
Baird Maintains Outperform on Regenxbio, R...
03/06/2024 12:55:28

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $34 to $39.

regenxbios-muscle-wasting-disorder-drug-shows-strength-improved-motor-function-stock-soars
REGENXBIO's Muscle Wasting Disorder Drug S...
03/05/2024 17:07:51

Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive result...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 13:09:49

regenxbio-announces-new-initial-efficacy-data-from-affinity-duchenne-trial
Regenxbio Announces New Initial Efficacy D...
03/05/2024 12:07:30

REGENXBIO Inc. (NASDAQ:RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® tr...

why-zscaler-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Zscaler Shares Are Trading Lower By 10...
03/01/2024 18:19:25

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION